持续皮下胰岛素输注市场（按产品类型、胰岛素类型、年龄层和最终用户）—2025-2032 年全球预测

预计到 2032 年持续皮下胰岛素输注市场将成长至 78.4 亿美元，复合年增长率为 12.51%。

主要市场统计数据
基准年2024年	30.5亿美元
预计2025年	34.3亿美元
预测年份：2032年	78.4亿美元
复合年增长率（%）	12.51%

不断发展的临床重点和技术正在将长效胰岛素转变为以患者为中心的互联治疗解决方案

在技​​术创新和护理模式转变的推动下，持续皮下胰岛素输注已从一种小众临床干预手段发展成为糖尿病治疗的核心方法。现代系统优先考虑以患者为中心的特性，例如易于使用、与血糖监测工具整合以及符合人体工学的设计。随着临床医生重视个人化血糖管理，设备开发商正致力于开发先进的输送机制、直觉的使用者介面以及支援远端监控和远端医疗工作流程的连接功能。

临床指南日益认可泵疗法在改善特定患者群体血糖稳定性方面的作用，而支付观点正在逐渐接受将其与改善预后和减少急性併发症联繫起来的证据。同时，监管框架日趋完善，以适应硬体和软体的迭代改进，使製造商无需重新设计整个设备平台即可推出增强功能。这些发展正在推动产品更新和软体主导功能的持续增加。

同时，患者的期望正转向侵入性更低、更能适应多样化生活方式的设备。这导致设计重点转向更小的尺寸、低调的佩戴体验和更简单的维护。同时，数据分析和互通性已成为差异化因素，使看护者和护理团队能够解读纵向血糖数据并优化治疗方案。这些因素共同构成了一个竞争格局，临床有效性、使用者体验和系统连结性将决定最终的竞争格局。

新的数位整合、自适应控制演算法和供应链现代化正在迅速改变胰岛素帮浦治疗和护理服务模式。

持续皮下胰岛素输注领域近期的转型变革反映了数位健康、设备小型化和一体化照护模式的融合，这些因素共同重塑了人们对治疗的期望。感测器精确度的提升和演算法的复杂度的提升，使得更聪明的胰岛素给药决策能够适应现实世界中的波动，例如活动、饮食和压力。因此，产品蓝图优先考虑闭合迴路相容性、自适应控制策略和安全资料交换，以支援纵向护理管理。

同时，製造和供应链策略也在不断发展，以适应电子和软体日益融合的趋势，鼓励现有设备製造商、半导体供应商和软体专家之间建立合作伙伴关係。这一趋势正在加快复杂组件的上市时间，并推动成本和采购方面的创新。监管机构正在透过完善软体验证和网路安全指南来应对这项挑战，以确保安全，同时又不会过度阻碍迭代创新。

同时，报销模式和医疗服务框架正在逐步调整，以支持居家慢性病管理，鼓励医疗服务提供者开立能够进行远端监控并减少住院治疗的设备。患者倡导和教育倡议透过揭开设备使用的神秘面纱并强调其对生活品质的益处，进一步推动了设备的采用。这些转变共同创造了一个充满活力的环境，在这个环境中，跨部门整合、证据生成和以使用者为中心的设计将决定长期的成功。

2025 年贸易政策的变化将迫使胰岛素供应利益相关人员重新设计敏捷的供应链、采取关税减免策略并采取策略性商业性应对措施

2025年关税和贸易政策调整的出台，对持续皮下胰岛素输注领域的製造商、经销商和医疗保健提供者而言，具有明显的营运和战略影响。采购团队必须重新评估筹资策略，以降低不断上升的到岸成本和潜在的前置作业时间波动。为此，企业正在评估替代製造布局，考虑近岸外包零件，并重新协商供应商合同，以分摊供应链各层级的关税风险。

除了采购之外，监管和合规部门正在重新调整文件和关税分类，以确保准确的关税处理，并在适用的情况下利用现有的优惠贸易计划。拥有模组化供应链和多元化供应商资源的公司表现出更强的韧性，而那些依赖少数海外供应商的公司更容易受到价格波动的影响。因此，策略规划现在融入了情境模型，以考虑关税波动对生产计划和客户定价的营运影响。

商业团队面临的挑战是，如何在需求敏感度下降的风险与成本吸收之间取得平衡，同时市场进入和可负担性。作为过渡策略，相关人员将采取有针对性的成本优化措施、渐进式价格调整和增强服务交付，以维护其价值提案。简而言之，贸易政策的转变凸显了敏捷的供应链设计、主动与监管机构的合作以及策略性商业规划的重要性，以保持连续性和竞争力。

产品架构、胰岛素配方、患者人口统计和医疗保健环境等多方面细分揭示了差异化的采用驱动因素和设计需求

严格的细分视角揭示了产品设计、胰岛素配方、患者人口统计和护理环境如何影响持续输註解决方案的采用和使用者体验。按产品类型分析时，传统系统和基于贴片的设备之间的差异会影响临床适用性和患者偏好。传统选项进一步分为电子泵和机械泵，电子主导平台提供可程式设计的输送模式、连接性和先进的安全联锁装置，而机械泵则强调针对特定用例的简单性和耐用性。关于胰岛素类型，速效类似物、常规胰岛素和短效製剂之间的选择会影响动态特征和给药演算法，从而为设备编程和临床滴定策略提供资讯。

年龄细分凸显了成人、老年人和儿童群体的不同需求。成人通常优先考虑生活方式的兼容性和个性化的连接性；老年人群体需要简化的界面和强大的安全功能，以减轻认知和灵活性的限制；儿科护理需要高度适应性的剂量范围、看护者控制能力和教育支持。最后，门诊护理、居家医疗和医院环境中的最终用户观点揭示了不同的采购驱动因素和营运要求。门诊环境优先考虑门诊病人管理的便携性和数据共用；居家医疗优先考虑易用性和长期依从性支持；医院环境优先考虑与电子健康记录的互通性、无菌输送通讯协定和急性血糖控制的可靠性。这种细分反映在产品开发、临床定位和商业化策略中，将技术能力与不同的现实世界需求相匹配。

美洲、欧洲、中东和非洲以及亚太地区的差异化将需要监管、报销和商业化方法

区域动态对持续输注技术的采用途径、报销架构和基础设施准备有重大影响。在美洲，医疗保健系统和付款人模式正在推动不同的采用场景，其中，整合护理网络和糖尿病管理项目中的先进采用优先考虑互联解决方案。因此，製造商将调整其临床参与和销售策略，以适应区域报销政策和专家培训计划。

欧洲、中东和非洲地区法规环境差异巨大，医疗保健服务可近性参差不齐，既带来了挑战，也带来了机会。一些欧洲市场强调严格的临床证据和数据隐私合规性，而其他市场则提供与公共卫生计划和基础设施投资相关的成长机会。因此，製造商必须采用差异化的打入市场策略，尊重当地监管要求，并利用合作管道进行临床医生教育。

亚太地区是一个复杂的区域，快速的都市化、不断扩张的私人医疗服务以及多元化的法律规范共同作用，这些框架鼓励城市地区采用创新技术，而都市区的医疗可及性仍是其战略考量。在所有地区，供应链的可靠性、本地监管的协调性以及符合当地文化的患者教育计画将决定创新技术的采用速度。因此，区域策略必须整合在地化的价值提案、在地相关人员的参与以及灵活的商业模式，以有效应对不同的医疗保健格局。

竞争格局由传统设备製造商、软体优先的参与企业和结果主导的服务模式决定，这些模式正在重新定义整个治疗生命週期的价值

竞争态势反映出老牌医疗设备製造商、新兴技术参与企业和专业组件供应商的整合，他们携手合作，共同提升持续输注能力。现有企业利用深厚的临床关係、监管经验和广泛的分销网络来维持其市场地位，而新参与企业则倾向于专注于软体创新、使用者体验和利基产品外形规格，以接触特定的患者群体。器械製造商和数位健康供应商之间的策略联盟加速了能力的整合，尤其是在闭合迴路相容性和数据分析服务方面。

随着相关人员寻求保护差异化特性，同时实现可控的互通性，与输液演算法、感测器互通性和网路安全相关的智慧财产权投资已成为战略重点。同时，服务导向的经营模式（例如捆绑远端监控订阅的设备以及整合的培训和依从性计划）正日益普及，创造了经常性收益流并增强了病人参与。采购和医院采购团队越来越多地将总体拥有成本与临床结果一起评估，鼓励供应商透过真实世界证据和上市后研究来证明其长期价值。

展望未来，竞争优势将在于那些能够兼具敏捷的监管、强大的品质和交付体系，以及清晰的产品服务策略，从而在整个治疗週期内为临床医生和患者提供支援的机构。能够透过与付款人、医疗服务提供者和患者组织合作，将技术优势与可衡量的医疗改进相结合的供应商，将进一步脱颖而出。

优先考虑互通性、供应多样性、现实世界证据和人性化的设计，以增强弹性并加速整个医疗环境中的采用

为了保持永续性并加速应用，产业领导者应优先制定策略议程，将产品创新与临床整合、供应链弹性和付款人参与度相结合。首先，投资可互通的平台和检验的演算法，以实现与血糖监测系统和电子健康记录进行有意义的数据交换。其次，实现製造和筹资策略的多元化，以减少贸易政策波动和零件短缺的风险，同时缩短中断情况下的恢復时间。

第三，我们将建立一个超越对照试验、涵盖真实世界临床试验、健康经济学分析和病人报告结果的证据产生项目。第四，我们将透过提供灵活的购买选项、服务包和临床医生培训，使我们的商业模式与当地支付方情况和最终用户需求一致，以降低应用门槛。第五，我们将融入人性化的设计原则，以满足不同年龄层患者的认知、感官和生活方式需求，从而提高依从性和满意度。

最后，在临床医生、付款人、病患权益组织和技术合作伙伴之间建立多方相关人员伙伴关係，共同打造兼顾临床有效性和实际操作的解决方案。透过实施这种多管齐下的策略，产业领导者可以增强韧性，创造差异化价值，并实现患者和护理团队的共同改善。

透明的混合方法研究框架，结合相关人员访谈、临床文献综合和供应链分析，以产生可操作的设备和商业性见解

调查方法整合了定性和定量分析，以确保全面洞察设备性能、相关人员的观点和营运限制。主要研究包括对临床医生、采购负责人和患者权益倡导者的结构化访谈，以了解设备可用性、临床工作流程整合以及与依从性相关的现实挑战的真实体验。这些访谈产生了主题分析，重点突出了连结性、剂量灵活性和看护者支持的通用痛点和机会领域。

二次研究综合了已发表的监管指南、临床文献和技术标准，为产品设计和核准提供见解。在适用的情况下，技术白皮书和同行评审的临床研究支援演算法方法和安全评估。我们利用贸易流量数据、采购出版物和供应商资讯披露信息，分析了供应链和贸易政策的影响，从而对运营漏洞和缓解策略形成了切合实际的认识。

最后，对一手资料和二手资料进行了交叉检验，以增强专题研究结果和建议的可信度。本调查方法强调透明度、可复製性和相关人员的相关性，同时考虑到地区差异和不断变化的监管预期，并支持为产品开发、商业化和策略规划提供可行的结论。

结合互通技术、操作灵活性和有针对性的证据产生的整合策略将决定输液治疗的长期成功

持续皮下胰岛素输注疗法正处于曲折点，技术成熟度、医疗模式的转变以及全球政策动态既带来了希望，也带来了复杂性。集强大的安全工程、无缝的数据整合和人性化的可用性于一体的设备将更有效地满足临床医生和患者的期望。同时，供应链的敏捷性和监管预见性对于在不断变化的贸易和合规环境中应对患者用药需求至关重要。

设备外形规格、胰岛素药理学、患者年龄相关需求以及护理环境要求之间的相互作用，凸显了细緻的产品系列和有针对性的临床参与的重要性。此外，竞争优势将有利于那些能够将技术差异化转化为检验的临床和经济效益的组织。总而言之，采用整合策略的相关人员，将互通技术、多元化企业发展、强有力的证据生成以及针对每个地区的定制方法相结合，将最有可能在糖尿病管理方面取得显着进展，并在动态治疗环境中保持长期增长。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 将连续血糖监测数据与先进的胰岛素帮浦演算法结合，可以在混合封闭回路型系统中预测胰岛素剂量调整。
• 开发具有智慧型手机连接和远端患者监护的无管贴片帮浦，以提高依从性
• 采用与胰岛素帮浦疗法相容的超速效胰岛素製剂来改善餐后血糖控制
• 根据即时生活方式数据实施个人化胰岛素剂量的人工智慧和机器学习模型
• 扩大报销框架和数位健康生态系统，以支援远端医疗启动和管理胰岛素帮浦治疗
• 製药和医疗设备製造商合作开发可互通的封闭回路型胰岛素输送解决方案
• 针对小儿患者，简化使用者介面和可自订设定的儿科胰岛素帮浦系统需求激增
• 引入可延长配戴时间的一次性贴片帮浦系统，以减轻使用者的设备维护负担

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 持续皮下胰岛素输注市场（依产品类型）

• 传统的
  • 电子底座帮浦
  • 机械帮浦
• 修补

9. 持续皮下胰岛素输注市场（依胰岛素类型）

• 速效类似物
• 常规胰岛素
• 短效

第 10 章。按年龄组别分類的持续皮下胰岛素输注市场

• 成人
• 老年人
• 孩子们

第 11 章。 持续皮下胰岛素输注市场（依最终用户）

• 门诊治疗
• 居家护理
• 医院

12. 持续性皮下胰岛素输注市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章持续皮下胰岛素输注市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

14. 持续皮下胰岛素输注市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Medtronic PLC
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Roche Diabetes Care AG
  • Ypsomed AG
  • Sooil Development Co., Ltd.
  • Medtrum Technologies, Inc.
  • Bigfoot Biomedical, Inc.
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • MicroPort Scientific Corporation

The Continuous Subcutaneous Insulin Infusion Market is projected to grow by USD 7.84 billion at a CAGR of 12.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 3.05 billion
Estimated Year [2025]	USD 3.43 billion
Forecast Year [2032]	USD 7.84 billion
CAGR (%)	12.51%

How evolving clinical priorities and technology convergence are reshaping continuous insulin delivery toward patient-centered, connected therapy solutions

Continuous subcutaneous insulin infusion has evolved from a niche clinical intervention to a central modality in diabetes care, driven by both technological innovation and shifting care paradigms. Modern systems prioritize patient-centric features such as usability, integration with glucose monitoring tools, and ergonomic design. As clinicians emphasize personalized glycemic management, device developers respond with refined delivery mechanisms, intuitive user interfaces, and connectivity that supports remote monitoring and telehealth workflows.

Clinical guidelines increasingly recognize the role of pump therapy in improving glycemic stability for selected patient populations, and payer perspectives are adapting to evidence that links improved outcomes with reduced acute complications. Meanwhile, regulatory pathways have matured to accommodate iterative improvements in hardware and software, which allows manufacturers to deploy enhancements without reworking entire device platforms. These developments encourage a steady cadence of product refreshes and software-driven feature additions.

At the same time, patient expectations have shifted toward minimally intrusive devices that fit diverse lifestyles. Consequently, design emphasis has moved toward smaller form factors, discreet wearability, and simplified maintenance. In parallel, data analytics and interoperability features have become differentiators, enabling caregivers and care teams to interpret longitudinal glucose data and optimize therapy. Taken together, these forces are shaping a landscape where clinical effectiveness, user experience, and system connectivity determine competitive positioning.

Emerging digital integration, adaptive control algorithms, and supply chain modernization are rapidly transforming insulin pump therapy and care delivery models

Recent transformative shifts in continuous subcutaneous insulin infusion reflect a convergence of digital health, device miniaturization, and integrated care models that together redefine therapeutic expectations. Advances in sensor accuracy and algorithm sophistication enable smarter insulin delivery decisions that adapt to real-world variability in activity, meals, and stress. As a result, product roadmaps prioritize closed-loop compatibility, adaptive control strategies, and secure data exchange to support longitudinal care management.

Simultaneously, manufacturing and supply chain strategies are evolving to accommodate higher integration of electronics and software, prompting collaborative partnerships between established device manufacturers, semiconductor suppliers, and software specialists. This trend reduces time to market for complex assemblies and drives innovation in cost and component sourcing. Regulatory bodies are responding by refining guidance on software validation and cybersecurity to ensure safety without unduly hindering iterative innovation.

In parallel, reimbursement models and care delivery frameworks are gradually aligning to support home-based chronic disease management, encouraging providers to prescribe devices that enable remote monitoring and reduce inpatient utilization. Patient advocacy and education initiatives further spur adoption by demystifying device use and emphasizing quality-of-life benefits. Collectively, these shifts create a dynamic environment where cross-functional integration, evidence generation, and user-centered design determine long-term success.

Trade policy shifts in 2025 compel agile supply chain redesign, tariff mitigation tactics, and strategic commercial responses across insulin delivery stakeholders

The introduction of tariffs and adjusted trade policies in 2025 has clear operational and strategic implications for manufacturers, distributors, and healthcare providers involved in continuous subcutaneous insulin infusion. Procurement teams must reassess sourcing strategies to mitigate increased landed costs and potential lead-time variability. In response, firms evaluate alternative manufacturing footprints, consider nearshoring components, and renegotiate supplier contracts to distribute tariff exposure across supply chain tiers.

Beyond procurement, regulatory and compliance functions are recalibrating documentation and customs classifications to ensure accurate duty treatment and to exploit available preferential trade programs where applicable. Firms with modular supply chains and diversified supplier pools demonstrate greater resilience, while those reliant on a narrow set of overseas suppliers face heightened vulnerability to price volatility. Consequently, strategic planning now integrates scenario modeling that examines the operational implications of tariff fluctuations on production schedules and customer pricing.

Commercial teams confront the challenge of preserving market access and affordability for patients, balancing cost absorption against the risk of reduced demand sensitivity. As transitional strategies, stakeholders pursue targeted cost optimization initiatives, incremental pricing adjustments, and enhanced service offerings to sustain value propositions. In short, trade policy shifts underscore the importance of agile supply chain design, proactive regulatory engagement, and strategic commercial planning to maintain continuity and competitiveness.

Multi-dimensional segmentation across product architecture, insulin formulations, patient age cohorts, and care settings reveals differentiated adoption drivers and design imperatives

A rigorous segmentation lens clarifies how product design, insulin formulations, patient demographics, and care settings shape adoption and user experience across continuous infusion solutions. When analyzed by product type, distinctions between Conventional systems and Patch-based devices influence clinical suitability and patient preference; Conventional options further differentiate into electronics-based pumps and mechanical pumps, with electronics-driven platforms offering programmable delivery patterns, connectivity, and advanced safety interlocks while mechanical pumps emphasize simplicity and durability for specific use cases. Regarding insulin type, choices among rapid-acting analogs, regular insulin, and short-acting formulations affect pharmacodynamic profiles and dosing algorithms, informing both device programming and clinical titration strategies.

Age group segmentation highlights divergent needs across adult, geriatric, and pediatric cohorts: adults often prioritize lifestyle compatibility and discrete connectivity, geriatric populations require simplified interfaces and robust safety features to mitigate cognitive or dexterity limitations, and pediatric care demands highly adaptable dosing ranges, caregiver control features, and educational supports. Finally, end-user perspectives spanning ambulatory care, homecare, and hospitals reveal distinct procurement drivers and operational requirements; ambulatory settings emphasize portability and data sharing for outpatient management, homecare focuses on ease of use and long-term adherence supports, and hospital environments prioritize interoperability with electronic health records, sterile supply protocols, and acute glycemic control reliability. Together, these segmentation dimensions inform product development, clinical positioning, and commercialization strategies that align technological capabilities with diverse real-world needs.

Regional differentiation across the Americas, Europe Middle East & Africa, and Asia-Pacific demands tailored regulatory, reimbursement, and commercialization approaches

Regional dynamics exert a powerful influence on adoption pathways, reimbursement frameworks, and infrastructure readiness for continuous infusion technologies. In the Americas, healthcare systems and payer models create varied uptake scenarios, with pockets of advanced adoption where integrated care networks and diabetes management programs prioritize connected solutions. Consequently, manufacturers orient clinical engagement and distribution strategies to align with regional reimbursement policies and specialist training programs.

In Europe, Middle East & Africa, heterogeneous regulatory environments and diverse healthcare access levels create both challenges and opportunities. Some European markets emphasize rigorous clinical evidence and data privacy compliance, while markets across the Middle East and Africa offer growth opportunities tied to public health initiatives and infrastructure investments. Manufacturers must therefore adopt differentiated market-entry strategies that respect local regulatory requirements and leverage partnership channels for clinician education.

Asia-Pacific presents a complex mix of rapid urbanization, expanding private healthcare provision, and varied regulatory frameworks that encourage innovation adoption in urban centers while rural access remains a strategic consideration. Across all regions, supply chain reliability, local regulatory harmonization, and culturally appropriate patient education programs determine the pace of adoption. As such, regional strategies must integrate tailored value propositions, local stakeholder engagement, and flexible commercial models to navigate distinct healthcare landscapes effectively.

Competitive landscape shaped by legacy device manufacturers, software-first entrants, and outcome-driven service models that redefine value across therapy lifecycles

Competitive dynamics reflect a blend of established medical device firms, emerging technology entrants, and specialized component suppliers collaborating to advance continuous infusion capabilities. Incumbent manufacturers leverage deep clinical relationships, regulatory experience, and broad distribution networks to maintain market presence, while newer entrants frequently emphasize software innovation, user experience, and niche form factors to capture specific patient segments. Strategic alliances between device makers and digital health vendors accelerate feature integration, particularly around closed-loop compatibility and data analytics services.

Investments in intellectual property around infusion algorithms, sensor interoperability, and cybersecurity represent strategic priorities, as stakeholders seek to protect differentiating features while enabling controlled interoperability. At the same time, service-oriented business models-such as bundled devices with remote monitoring subscriptions or integrated training and adherence programs-gain traction, creating recurring revenue streams and enhanced patient engagement. Procurement and hospital sourcing teams increasingly evaluate total cost of ownership alongside clinical outcomes, which encourages vendors to demonstrate longitudinal value through real-world evidence and post-market studies.

Looking ahead, competitive advantage will accrue to organizations that combine regulatory agility, robust quality and supply systems, and a clear product-service strategy that supports clinicians and patients through the entire therapy lifecycle. Collaboration with payers, providers, and patient groups will further distinguish vendors able to translate technical features into measurable care improvements.

Prioritize interoperability, supply diversification, real-world evidence, and human-centered design to strengthen resilience and accelerate adoption across care settings

Industry leaders should prioritize a strategic agenda that aligns product innovation with clinical integration, supply chain resilience, and payer engagement to preserve sustainability and accelerate adoption. First, invest in interoperable platforms and validated algorithms that enable meaningful data exchange with glucose monitoring systems and electronic health records; this foundation supports clinician workflows and enhances the clinical utility of therapy data. Second, diversify manufacturing and sourcing strategies to reduce exposure to trade policy volatility and component shortages while accelerating time to recovery in the event of disruption.

Third, build evidence-generation programs that go beyond controlled trials to include real-world studies, health economic analyses, and patient-reported outcomes; these data strengthen reimbursement conversations and inform iterative design improvements. Fourth, tailor commercial models to regional payer landscapes and end-user needs by offering flexible purchasing options, service bundles, and clinician training that lower barriers to adoption. Fifth, embed human-centered design principles to ensure devices meet the cognitive, sensory, and lifestyle needs of varied age groups, thereby improving adherence and satisfaction.

Finally, cultivate multi-stakeholder partnerships spanning clinicians, payers, patient advocacy groups, and technology partners to co-create solutions that align clinical efficacy with practical implementation. By executing this multipronged strategy, industry leaders will enhance resilience, foster differentiated value, and deliver improved outcomes for patients and care teams alike.

A transparent mixed-methods research framework combining stakeholder interviews, clinical literature synthesis, and supply chain analysis to produce actionable device and commercial insights

The research approach integrates qualitative and quantitative methods to ensure comprehensive insight into device performance, stakeholder perspectives, and operational constraints. Primary research included structured interviews with clinicians, procurement officers, and patient advocates to capture firsthand experience with device usability, clinical workflow integration, and real-world adherence challenges. These conversations informed thematic analysis that highlights common pain points and opportunity areas related to connectivity, dosing flexibility, and caregiver support.

Secondary research synthesized publicly available regulatory guidance, clinical literature, and technical standards to contextualize product design and approval considerations. Where applicable, technical white papers and peer-reviewed clinical studies supported assessments of algorithmic approaches and safety considerations. Supply chain and trade policy impacts were analyzed using trade flow data, procurement publications, and supplier disclosures to develop a pragmatic view of operational vulnerabilities and mitigation levers.

Finally, cross-validation exercises reconciled primary insights with secondary sources to increase confidence in thematic findings and recommendations. The methodology emphasizes transparency, reproducibility, and stakeholder relevance, and it supports actionable conclusions for product development, commercialization, and strategic planning while acknowledging regional variability and evolving regulatory expectations.

An integrated strategy combining interoperable technology, operational agility, and targeted evidence generation will determine long-term success in infusion therapy

Continuous subcutaneous insulin infusion stands at an inflection point where technological maturation, shifting care models, and global policy dynamics converge to create both promise and complexity. Devices that marry robust safety engineering with seamless data integration and human-centered usability will meet clinician and patient expectations more effectively. At the same time, supply chain agility and regulatory foresight are crucial to navigate evolving trade and compliance landscapes without interrupting patient access.

The interplay between device form factor, insulin pharmacology, patient age-related needs, and care setting requirements underscores the importance of nuanced product portfolios and targeted clinical engagement. Moreover, competitive advantage will favor organizations that can translate technical differentiation into verifiable clinical and economic benefits. In conclusion, stakeholders who adopt an integrated strategy-combining interoperable technology, diversified operations, strong evidence generation, and tailored regional approaches-will be best positioned to deliver meaningful improvements in diabetes management and to sustain long-term growth in a dynamic therapeutic environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of continuous glucose monitoring data with advanced insulin pump algorithms enabling predictive insulin dosing adjustments in hybrid closed-loop systems
• 5.2. Development of tubeless patch pumps with smartphone connectivity and remote patient monitoring capabilities for enhanced adherence
• 5.3. Adoption of ultra-rapid-acting insulin formulations compatible with insulin pump therapy to improve postprandial glucose control
• 5.4. Implementation of artificial intelligence and machine learning models for personalized insulin delivery based on real-time lifestyle data
• 5.5. Expansion of reimbursement frameworks and digital health ecosystems to support telehealth initiation and management of insulin pump therapy
• 5.6. Collaboration between pharmaceutical companies and medical device manufacturers to co-develop interoperable closed-loop insulin delivery solutions
• 5.7. Surging demand for pediatric insulin pump systems featuring simplified user interfaces and customizable settings for young patients
• 5.8. Emergence of disposable patch pump systems with extended wear duration to reduce device maintenance burden for users

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Continuous Subcutaneous Insulin Infusion Market, by Product Type

• 8.1. Conventional
  • 8.1.1. Electronics Based Pumps
  • 8.1.2. Mechanical Pumps
• 8.2. Patch

9. Continuous Subcutaneous Insulin Infusion Market, by Insulin Type

• 9.1. Rapid Acting Analog
• 9.2. Regular Insulin
• 9.3. Short Acting

10. Continuous Subcutaneous Insulin Infusion Market, by Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Continuous Subcutaneous Insulin Infusion Market, by End User

• 11.1. Ambulatory Care
• 11.2. Homecare
• 11.3. Hospitals

12. Continuous Subcutaneous Insulin Infusion Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Continuous Subcutaneous Insulin Infusion Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Continuous Subcutaneous Insulin Infusion Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. Medtronic PLC
  • 15.3.2. Insulet Corporation
  • 15.3.3. Tandem Diabetes Care, Inc.
  • 15.3.4. Roche Diabetes Care AG
  • 15.3.5. Ypsomed AG
  • 15.3.6. Sooil Development Co., Ltd.
  • 15.3.7. Medtrum Technologies, Inc.
  • 15.3.8. Bigfoot Biomedical, Inc.
  • 15.3.9. B. Braun SE
  • 15.3.10. Baxter International, Inc.
  • 15.3.11. Becton, Dickinson and Company
  • 15.3.12. MicroPort Scientific Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ELECTRONICS BASED PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY MECHANICAL PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY RAPID ACTING ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGULAR INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SHORT ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 97. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 99. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 101. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 103. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 105. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 107. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 110. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 111. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 112. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 113. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 114. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 115. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 116. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 117. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 118. NORTH AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 119. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 122. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 123. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 124. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 125. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 126. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 127. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 128. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 130. LATIN AMERICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 143. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 146. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 147. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 148. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 149. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 150. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 151. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 152. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 153. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. EUROPE CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 155. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 158. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 160. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 162. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 164. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. MIDDLE EAST CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 167. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 170. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 171. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 172. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 173. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 174. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 175. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 176. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 177. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. AFRICA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 182. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 184. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 186. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 188. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 189. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. ASIA-PACIFIC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 196. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 197. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 198. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 199. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 200. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 201. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 202. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 203. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. ASEAN CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 205. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 209. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 210. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 211. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 212. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 213. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 214. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 215. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 216. GCC CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 222. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 223. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 224. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 225. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 226. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 227. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. EUROPEAN UNION CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 232. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 233. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 234. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 235. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 236. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 237. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 238. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 239. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 240. BRICS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 241. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 242. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 243. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 244. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 245. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 246. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 247. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 248. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 249. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 250. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 251. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. G7 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 257. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 258. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 259. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 260. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 261. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 262. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 263. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. NATO CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 267. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 269. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 270. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 271. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 272. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 273. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 274. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
• TABLE 275. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 276. UNITED STATES CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 277. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 278. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 279. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
• TABLE 280. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
• TABLE 281. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
• TABLE 282. CANADA CONTINUOUS SUBCUTANEOUS INSULIN INFUSION MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
• TABLE 283. CANADA CONTINUOUS SUBC